Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Filings indexed 339 across all filing types
Latest filing 2026-02-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics - Attachment: Inify_Laboratories_year_end_report_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Year-end report for the fourth quarter and full year 2025' for Inify Laboratories. It contains comprehensive financial statements, key performance indicators (EBITDA, sales, cash flow), management commentary, and operational updates for the specified period. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. Q4 2025
2026-02-25 English
Inify Laboratories: Stabil försäljningstillväxt, stark utveckling i Storbritannien och positiv respons på gastrointestinal diagnostik
Earnings Release Classification · 95% confidence The document is a press release from Inify Laboratories dated February 25, 2026, detailing financial performance highlights for the fourth quarter of 2025, including sales growth, operational updates in the UK, and information regarding a capital raise. It follows the standard format of an earnings release, providing key highlights and management commentary rather than a full comprehensive financial report. It does not meet the criteria for a full 10-K or Interim Report, nor is it a mere announcement of a report publication. Q4 2025
2026-02-25 Swedish
Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics
Earnings Release Classification · 95% confidence The document is a press release announcing quarterly financial and operational highlights for Inify Laboratories. It summarizes sales growth, progress in the UK market, and the launch of new services. While it mentions financial results, it is a high-level summary (Earnings Release) rather than a full quarterly report or a report publication announcement. It fits the definition of an Earnings Release (ER) as it provides key highlights of the period's performance. Q4 2025
2026-02-25 English
Correction: Inify Laboratories - mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is a standard notification form for a person discharging managerial responsibilities (PDMR), specifically detailing a transaction (subscription of shares) by a member of the board of directors. This falls under the category of Director's Dealing, which tracks personal share transactions by company executives and directors.
2026-01-30 English
Correction: Inify Laboratories - mandatory notification of trade - Attachment: Inify_Laboratories_PDMR_attachment_corrected_.pdf
Director's Dealing Classification · 100% confidence The document is a standard notification form for a person discharging managerial responsibilities (PDMR), specifically detailing a transaction (subscription of shares) by a member of the board of directors. This falls under the category of Director's Dealing, which tracks personal share transactions by company executives and directors.
2026-01-30 English
Correction: Inify Laboratories - mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is a correction notice regarding a previous announcement of share allocation to a board member (Martin Ingvar). It explicitly references the EU Market Abuse Regulation (EU 596/2014 article 19), which governs the disclosure of transactions by persons discharging managerial responsibilities (PDMRs). Since this document reports a specific transaction/holding update for a director, it falls under the category of Director's Dealing.
2026-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.